California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals
Certain ICD-9-CM* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.
Note: Casefinding codes for borderline ovarian tumors (235.0-236.6) are included in the Supplementary List #2.
Historical ICD-9-CM Codes:
The following information is taken directly from the SEER web site: http://seer.cancer.gov/tools/casefinding/case2013long.html.
These tables are also available in a printable version (PDF): http://seer.cancer.gov/tools/casefinding/fy2013_casefindinglist_long.pdf.
2013 Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors
(with equivalent ICD-10-CM codes**) (Effective Date: 1/1/2013)
Please refer to your standard setter(s) for specific reporting requirements
before using the Casefinding List
ICD-9-CM Code* |
ICD-10-CM Code** |
Explanation of ICD-9-CM Code |
140._ - 172._ 174._ - 209.36 209.7_ |
C00._ - C43._ C45._ - C96._ |
Malignant neoplasms (excluding category 173) , stated or presumed to be primary (of specified sites), and certain specified histologies |
173.00 173.09 |
C44.00 C44.09 |
Unspecified and other specified malignant neoplasm of skin of lip |
173.10 173.19 |
C44.101 C44.191 |
Unspecified and other specified malignant neoplasm of eyelid, including canthus |
173.20 173.29 |
C44.201 C44.291 |
Unspecified and other specified malignant neoplasm of ear and external auricular canal |
173.30 173.39 |
C44.30 C44.39 |
Unspecified and other specified malignant neoplasm of skin of other and unspecified parts of face |
173.40 173.49 |
C44.40 C44.49 |
Unspecified and other specified malignant neoplasm of scalp and skin of neck |
173.50 173.59 |
C44.50_ C44.59_ |
Unspecified and other specified malignant neoplasm of skin of trunk, except scrotum |
173.60 173.69 |
C44.601 C44.691 |
Unspecified and other specified malignant neoplasm of skin of upper limb, including shoulder |
173.70 173.79 |
C44.701 C44.791 |
Unspecified and other specified malignant neoplasm of skin of lower limb, including hip |
173.80 173.89 |
C44.80 C44.89 |
Unspecified and other specified malignant neoplasm of other specified sites of skin |
173.90 173.99 |
C44.90 C44.99 |
Unspecified and other specified malignant neoplasm of skin, site unspecified |
225.0 - 225.9 |
D32._ - D33._ |
Benign neoplasm of brain and spinal cord neoplasm |
227.3 227.4 |
D35.2 D35.3 |
Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland |
228.02 |
D18.02 |
Hemangioma; of intracranial structures |
228.1 |
D18.1 |
Lymphangioma, any site |
230.0 - 234.9 |
D00._ - D09._ |
Carcinoma in situ |
237.0 - 237.1 |
D44.3 - D44.5 |
Neoplasm of uncertain behavior of endocrine glands and nervous system: pituitary gland, carniopharyngeal duct and pineal gland |
237.5 237.6 237.9 |
D42._ D43.0_ |
Neoplasm of uncertain behavior of endocrine glands and nervous system: brain and spinal cord, meninges, endocrine glands and other and unspecified parts of nervous system |
238.4 |
D45 |
Polycythemia vera |
238.6 |
D47.Z9 |
Plasma cells |
238.7_ |
D46._ D47._ |
Other lymphatic and hematopoietic diseases |
239.6 239.7 |
D49.6 |
Neoplasms of unspecified nature, brain, endocrine glands and other parts of nervous system |
273.3 |
C88.0 |
Macroglobulinemia (Waldenstrom’s macroglobulinemia) |
277.89 |
C96.5 C96.6 |
Other specified disorders of metabolism |
288.4 |
D76.1 - D76.3 |
Hemophagocytic syndrome (histiocytic syndromes) |
289.6 |
D45 |
Familial polycythemia (synonym for polycythemia vera) |
2013 Supplementary List #1 ICD-9-CM Codes That Should be Followed by or Associated with a Neoplasm Code (with Equivalent ICD-10-CM Codes)
ICD-9-CM Code* |
ICD-10-CM Code** |
Explanation of ICD-9-CM Code |
258.0_ |
E31.22, E31.23 |
Polyglandular activity in multiple endocrine adenomatosis
[MEN] |
284.2 |
D61.82 |
Myelophthisis |
285.22 |
D63.0 |
Anemia in neoplastic disease |
289.83 |
D75.81 |
Myelofibrosis (9961/3) |
331.7 |
G94 |
Cerebral degeneration in diseases classified elsewhere |
336.3 |
G99.2 |
Myelopathy in other diseases classified elsewhere |
357.3 |
G13.0, G13.1 |
Polyneuropathy in malignant disease |
358.1 |
G73.3 |
Myasthenic syndromes in other diseases classified
elsewhere |
358.31 |
G73.1 |
Eaton-Lambert syndrome in neoplastic disease |
511.81 |
J91.0 |
Malignant pleural effusion |
512.82 |
J93.12 |
Secondary spontaneous pneumothorax |
731.1_ |
M90.6_ |
Osteitis deformans in diseases classified elsewhere |
731.3 |
M89.70_ |
Major osseous defect |
789.51 |
R18.0 |
Malignant ascites |
V07.5_ |
Z79.81_ |
Prophylactic use of agents affecting estrogen receptors
and estrogen levels |
V58.42 |
Z48.3 |
Aftercare following surgery for neoplasm |
Note: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Experience in the SEER registries has shown that using the supplementary list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.
2013 Supplementary List #2 ICD-9-CM Code List to Screen for Cancer Registry Cases Not Identified by Other Codes (with equivalent ICD-10-CM codes)
ICD-9-CM Code* |
ICD-10-CM Code** |
Explanation of ICD-9-CM Code |
042 |
B20 |
Acquired Immunodeficiency Syndrome (AIDS) |
079.4 79.5_ |
B97.7 |
Human papillomavirus; Retrovirus (HTLV, types I, II and 2) |
173.01 173.02 |
C44.01 C44.02 |
Basal and squamous cell carcinoma of skin of lip |
173.11 173.12 |
C44.111 C44.121 |
Basal and squamous cell carcinoma of eyelid, including canthus |
173.21 173.22 |
C44.211 C44.221 |
Basal and squamous cell carcinoma of ear and external auricular canal |
173.31 173.32 |
C44.31_ C44.32_ |
Basal and squamous cell carcinoma of skin of other and unspecified parts of face |
173.41 173.42 |
C44.41 C44.42 |
Basal and squamous cell carcinoma of scalp and skin of neck |
173.51 173.52 |
C44.51_ C44.52_ |
Basal and squamous cell carcinoma of skin of trunk, except scrotum |
173.61 173.62 |
C44.611 C44.621 |
Basal and squamous cell carcinoma of skin of upper limb, including shoulder |
173.71 173.72 |
C44.711 C44.721 |
Basal and squamous cell carcinoma of skin of lower limb, including hip |
173.81 173.82 |
C44.81 C44.82 |
Basal and squamous cell carcinoma of other specified sites of skin |
173.91 173.92 |
C44.91 C44.92 |
Basal and squamous cell carcinoma of skin, site unspecified |
209.40 - 209.69 |
D3Aa._ |
Benign carcinoid tumors |
210.0 - 229.9 |
D10._ – D31._ D34 D35.0 D35.1 D35.5 – D35.9 D36._ |
Benign neoplasms (except for 225.0-225.9, 227.3,
227.4, 228.02, 228.1, which are listed in the Reportable list) |
235.0 - 236.99 |
D37 ._ - D41._ |
Neoplasms of uncertain behavior |
237.2 - 237.4 |
D44.1 D44.2 D44.6 - D44.9 |
Neoplasm of uncertain behavior of adrenal gland,
paraganglia and other and unspecified endocrine glands |
237.7_ |
Q85._ |
Neurofibromatosis and Schwannomastosis |
238.0 - 239.9 |
D48._ D49._ |
Neoplasms of uncertain behavior (except for 238.4,
238.71-238.79, 239.6, 239.7, which are listed in the reportable
list) |
249.20 |
E08._ |
Secondary diabetes mellitus with hypersmolarity |
273.0 |
D89.0 |
Polyclonal hypergammaglobulinemia |
273.1 |
D47.2 |
Monoclonal gammopathy of undetermined significance
(9765/1) |
273.2 |
D89.1 |
Other paraproteinemias |
273.8 273.9 |
E88.09 |
Other and unspecified disorders of plasma protein
metabolism |
277.88 |
E88.3 |
Tumor lysis syndrome (following neoplastic chemotherapy) |
279.02 279.03 279.05 279.12 |
D80.3 D80.4 D80.5 |
Select IgM immunodeficiency and other immunoglobulin
deficiencies |
279.2 279.3 |
D81.0 - D81.2 D81.6 D81.7 D81.89 D81.9 D84.9 |
Combined and unspecified immunity deficiency |
279.41 279.49 |
D89.82 D89.89 |
Autoimmune lymphoproliferative syndrome |
279.50 - 279.53 |
D89.81_ |
Graft-versus-host disease |
279.8 279.9 |
D84.1 D89.82 D89.9 |
Other and unspecified disorders involving the immune
mechanism |
284.1_ |
D61.8_ |
Pancytopenia |
284.81 |
D60._ |
Red cell aplasia (acquired) (adult) (with thymoma) |
284.89 |
D61.1 - D61.3 D61.89 D61.9 |
Other specified aplastic anemias |
284.9 |
D61.9 |
Aplastic anemia |
285.0 |
D64.01 - D64.4 |
Sideroblastic anemia |
285.3 |
D64.81 |
Anemia due to antineoplastic chemotherapy |
287.39 287.49 287.5 |
D69.49 D69.59 D69.6 |
Secondary, other primary and unspecified thrombocytopenia |
288.03 |
D70.1 |
Drug induced neutropenia |
288.3 |
D72.1 |
Eosinophilia |
289.89 289.9 |
D75.89 D75.9 D89.2 |
Other and unspecified diseases of blood and blood
forming organs |
323.81 |
G04.81 |
Other causes of encephalitis and encephalomyelitis |
337.9 |
G90.9 |
Unspecified disorders of autonomic nervous system |
338.3 |
G89.3 |
Neoplasm related pain (acute)(chronic) |
352.9 |
G52.9 |
Unspecified disorder of cranial nerves |
353.8 |
G54.8 |
Other nerve root and plexus disorders |
516.5 |
J84.82 |
Adult pulmonary Langerhans cell histiocytosis |
569.44 |
K62.82 |
Dysplasia of anus (Anal intraepithelial neoplasia [AIN I and II]) |
602.3 |
N42.3 |
Dysplasia of prostate (Prostatic intraepithelial neoplasia [PIN I and II]) |
622.10 |
N87.9 |
Dysplasia of cervix, unspecified; cervical dysplasia, NOS |
622.11 |
N87.0 |
Mild dysplasia of cervix [CIN I] |
622.12 |
N87.1 |
Moderate dysplasia of cervix [CIN II] |
623.0 |
N89._ |
Dysplasia of vagina (Vaginal intraepithelial neoplasia [VAIN I and II] |
624.01 |
N90.0 N90.3 |
Vulvar intraepithelial neoplasia I [VIN I] & unspecified |
624.02 |
N90.1 |
Vulvar intraepithelial neoplasia II [VIN II] |
630 |
O01._ |
Hydatidiform mole |
648.9_ |
O9A.1_ |
Other current conditions classifiable elsewhere
complicating pregnancy |
713.8 |
M36.1 |
Arthropathy associated with other conditions |
728.9 |
M62.9 |
Unspecified disorder of muscle, ligament, and fascia |
733.1_ |
M84.5_ |
Pathologic fracture |
758.0 |
Q90.0_ |
Down's Syndrome |
780.79 |
R53.0 |
Neoplastic (malignant) related fatigue |
785.6 |
R59._ |
Enlargement of lymph nodes |
789.51 |
R18.0 |
Malignant ascites |
790.93 |
R97.2 |
Elevated prostate specific antigen (PSA) |
791.9 |
R82.8 |
Other non specific findings on examination of urine(abnormal findings on cytological and histological examination of urine) |
792.0 792.2 792.4 792.9 |
R83.9 R84.9 R85.9 R86.9 |
Non specific abnormal findings in other body structures: cerebrospinal fluid, semen and saliva and other |
793.11 |
R91.1 |
Solitary pulmonary nodule |
793.8_ |
R92._ |
Nonspecific (abnormal) findings on radiological and examination of body structure (breast) |
795.0_ - 795.1_ |
R87.6_ |
Papanicolaou smear of cervix and vagina with cytologic evidence of malignancy |
795.4 |
R89.7 |
Other nonspecific abnormal histological findings |
796.7_ |
R85.6_ |
Abnormal cytologic smear of anus and anal HPV |
795.8_ |
R97._ |
Abnormal tumor markers; Elevated tumor associated antigens [TAA] |
962.1 |
T38.6_ |
Poisoning by hormones and synthetic substitutes: Androgens and anabolic congeners |
963.1 |
T45.1_ |
Poisoning by primarily systemic agents: antineoplastic and immunosuppressive drugs |
990 |
T66 |
Effects of radiation, unspecified (radiation sickness) |
996.54 |
T85.4_ |
Mechanical complication of other specified prosthetic device, implant, and graft-due to breast prosthesis |
996.85 |
T86.0_ |
Complication of transplanted organ |
999.3_ |
T80.2_ |
Complications due to central venous catheter |
E858.0 |
T38.6_ |
Accidental poisoning by other drugs: Hormones and synthetic substitutes |
E858.1 |
T45.1_ |
Accidental poisoning by other drugs: Primary systemic agents |
E858.2 |
T45.8_ T45.9_ |
Agents primarily affecting blood constituents |
E873.2 |
Y63.2 |
Failure in dosage, overdose of radiation in therapy (radiation sickness) |
E878.0 |
Y83.0 |
Abnormal reaction of surgical operation with transplant of whole organ |
E879.2 |
Y84.2 |
Overdose of radiation given during therapy (radiation sickness) |
E930.7 |
None |
Adverse reaction of antineoplastic therapy-Antineoplastic antibiotics |
E932.1 |
None |
Adverse reaction to antineoplastic therapy-Androgens and anabolic congeners |
E933.1 |
None |
Adverse effect (poisoning) of immunosuppressive drugs |
V10.0_ - V10.9_ |
Z85.0_ - Z85.8_ |
Personal history of malignancy |
V12.41 |
Z86.011 |
Personal history of benign neoplasm of the brain |
V13.89 |
Z86.000 Z86.008 Z86.011 |
Personal history of unspecified malignant neoplasm and history of in-situ neoplasm of other site |
V15.22 |
Z98.871 |
Personal history of undergoing in utero procedure
during pregnancy |
V15.3 |
Z92.3 |
Other personal history presenting hazards to health
or radiation |
V16._ |
Z80._ |
Family history of malignant neoplasm |
V42.81 V42.82 |
Z94.81 Z94.84 |
Organ or tissue replaced by transplant bone marrow, stem cell |
V51.0 |
Z42.1 |
Encounter for breast reconstruction following mastectomy |
V52.4 |
Z44.3_ |
Fitting and adjustment of prosthetic device and implant (breast) |
V54.2_ |
M84.5_ |
Aftercare for healing pathologic fracture |
V58.0 V58.1_ |
Z51.0 Z51.1_ |
Encounter for radiotherapy, chemotherapy, immunotherapy |
V58.42 |
M84.4_ |
Aftercare following surgery for neoplasm |
V66.1 V66.2 |
Z51.89 |
Convalescence and palliative care following radiotherapy, chemotherapy |
V66.7 |
Z51.5 |
Encounter for palliative care |
V67.1 V67.2 |
Z08 |
Follow up examination: following radiotherapy or chemotherapy |
V71.1 |
Z03.89 |
Observation for suspected malignant neoplasm |
V72.83 |
Z01.818 |
Other specified pre-operative examination (including chemotherapy) |
V76._ |
Z12._ |
Special screening for malignant neoplasms |
V78.8 V78.9 |
Z13.0 |
Other and unspecified disorders of blood and blood forming organs |
V86 ._ |
Z17 ._ |
Estrogen receptor positive status [ER+], negative status [ER-] |
V87.41 |
Z92.21 |
Personal history of antineoplastic chemotherapy |
V87.43 |
Z92.23 |
Personal history of estrogen therapy |
V87.46 |
Z92.25 |
Personal history of immunosuppression therapy |
The following codes are associated with the paraneoplastic syndrome. Paraneoplastic syndrome by itself is not cancer. It’s a disease or symptom that is the consequence of cancer but is not due to the local presence of cancer cells. A paraneoplastic syndrome may be the first sign of cancer. These codes have been removed from the supplemental list and are now in their own list.
ICD-9-CM Code* |
ICD-10-CM Code** |
Explanation of ICD-9-CM Code |
253.6 |
E22.2 |
Syndrome of inappropriate secretion of antidiuretic hormone |
259.2 |
E34.0 |
Carcinoid syndrome |
259.8 |
E34.8 |
Other specified endocrine disorders |
275.42 |
E83.52 |
Hypercalcemia |
379.5_ |
H55._ |
Nystagmus and other irregular eye movements |
686.01 |
L88 |
Pyoderma gangrenosum |
694.4 |
L10.81 |
Pemphigus |
695.89 |
L30.4 L53.8 L98.2 |
Other specified erythematous conditions |
701.2 |
L83 |
Acquired acanthosis nigricans |
710.3 |
M36.0 |
Dermatomyositis |
710.4 |
M33.2_ |
Polymyositis |
*International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, 2013.
**All information regarding ICD-10-CM, including the conversions of ICD-9-CM to ICD-10-CM based on the 2013 General Equivalency Mappings provided by CMS and NCHS on the CDC website for ICD coding: http://www.cdc.gov/nchs/icd/icd10cm.htm